Tag Archives: MEK inhibitor

December, 2017

20 December
Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations

BOULDER, Colo., Dec. 19, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array’s MEK inhibitor, binimetinib, with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab*, a …
Share

8 May
Array BioPharma Enter Strategic Collaboration with Merck in Colorectal Cancer

BOULDER, Colo., May 8, 2017 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to investigate the safety and efficacy of Array’s MEK inhibitor, binimetinib, with Merck’s anti-PD-1 therapy, …
Share

9 August
AstraZeneca’s NSCLC Candidate Fails in Late-Stage Trial

AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The results showed that the trial did not meet its primary endpoint …
Share

12 May
AstraZeneca’s Thyroid Cancer Drug Granted Orphan Drug Status from the FDA

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC). DTC is diagnosed in approximately 60,000 people in the US each …
Share

6 October
Exelixis Announces Positive Results for its Late-Stage Melanoma Trial

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 6, 2015– Exelixis, Inc.(NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 …
Share